SCHEMBL8574359

SCHEMBL8574359

CON(C)C(=O)c1cc(Cl)ccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
TP53 P04637 2/20 0.52
HPGD P15428 2/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 2/20 0.46
PKM P14618 1/20 0.46
SLC6A3 Q01959 2/20 0.46
CXCL12 P48061 1/20 0.44
LMNA P02545 2/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
ABCB1 P08183 1/20 0.43
ERCC5 P28715 1/20 0.42
FEN1 P39748 1/20 0.42
FSCN1 Q16658 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008380 0.86 CYP3A4 (0.54) ALDH1A1RAB9APKMCXCL12TSHR
SCHEMBL305871 0.85 SLC6A3 (0.48) ALDH1A1RAB9APKMSLC6A3LMNA
SCHEMBL29554674 0.85 PKM (0.45) ALDH1A1TP53HPGDHTTRAB9A
SCHEMBL19285067 0.85 PKM (0.45) ALDH1A1TP53HPGDHTTRAB9A
SCHEMBL12900958 0.85 PKM (0.45) ALDH1A1TP53HPGDHTTRAB9A
SCHEMBL25298572 0.83 ALDH1A1 (0.45) ALDH1A1HPGDRAB9APKMSLC6A3
SCHEMBL307646 0.83 ALDH1A1 (0.45) ALDH1A1TP53RAB9APKMSLC6A3
SCHEMBL153277 0.83 ALDH1A1 (0.71) ALDH1A1HPGDHTTPKMSLC6A3
SCHEMBL5623892 0.83 TSHR (0.57) ALDH1A1TP53HTTRAB9ALMNA
SCHEMBL26732 0.83 ABL1 (0.49) ALDH1A1HPGDHTTRAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2021-02-11 US disclosed
US-10723708-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2020-07-28 US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 US disclosed
EP-2570414-B1 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL MYERS SQUIBB CO (US) 2017-08-30 EP disclosed
US-8557841-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-15 US disclosed
EP-2570414-A1 Heterocyclic aromatic compounds useful as growth hormone secretagogues Bristol-Myers Squibb Company (US) 2013-03-20 EP disclosed
US-20120252799-A1 HETEROCYCLIC AROMATIC COMPOUNDS USEFUL AS GROWTH HORMONE SECRETAGOGUES BRISTOL-MYERS SQUIBB COMPANY (US) 2012-10-04 US disclosed
US-8232291-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-31 US disclosed
US-20110224199-A1 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2011-09-15 US disclosed
US-20100016233-A1 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-21 US disclosed
US-20090324625-A1 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-31 US disclosed
US-20090324625-A1 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-31 US disclosed
US-7592354-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-22 US disclosed
US-7592354-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-22 US disclosed
US-7589102-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-15 US disclosed
US-7589102-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-15 US disclosed
US-7166596-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB CO. (US) 2007-01-23 US disclosed
US-7166596-B2 Heterocyclic aromatic compounds useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB CO. (US) 2007-01-23 US disclosed
US-5739336-A SELECTIVE 5-HYDROXYTRYPTAMINE-2C RECEPTOR ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1998-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324625-A1 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues GHSR, GHRHR, NPY1R ALDH1A1 3846/4885TP53 4464/4885HPGD 646/4885
US-10723708-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 ALDH1A1 3921/4885TP53 511/4885HPGD 3407/4885
US-20100016233-A1 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues GHSR, GHRHR, NPY1R ALDH1A1 3846/4885TP53 4464/4885HPGD 646/4885
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 ALDH1A1 3921/4885TP53 511/4885HPGD 3407/4885
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 ALDH1A1 3921/4885TP53 511/4885HPGD 3407/4885
US-20110224199-A1 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues GHSR, GHRHR, NPY1R ALDH1A1 3846/4885TP53 4464/4885HPGD 646/4885
US-20120252799-A1 HETEROCYCLIC AROMATIC COMPOUNDS USEFUL AS GROWTH HORMONE SECRETAGOGUES GHSR, GHRHR, NPY1R ALDH1A1 3846/4885TP53 4464/4885HPGD 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.